Clinical Trial Update: A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a single vaccination of an Ad26.preF-based RSV vaccine in healthy Japanese adults aged 60 years and older has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Disease

Drugs mentioned

• Ad26.preF-based RSV vaccine (Adenovirus serotype 26, pre-fusion F RSV vaccine)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Healthy | Phase 1 | Status: COMPLETED